Edwards Lifesciences reported second quarter 2026 sales of $1.74 billion, a 13.6% increase year-over-year, with constant currency sales growing 12.5%. Transcatheter Aortic Valve Replacement (TAVR) sales rose 11.3% to $1.26 billion, while Transcatheter Mitral and Tricuspid Therapies (TMTT) sales grew 47.3% to $195.9 million. The company reported GAAP diluted earnings per share of $0.42 and adjusted EPS of $0.78. Based on these results, Edwards increased its full-year 2026 total sales growth guidance to 10% to 11% from 9% to 11% and raised its TAVR constant currency sales growth guidance to 8% to 9%. The company is a medical device manufacturer specializing in structural heart innovation.
